Sotorasib in combination with panitumumab in refractory KRAS G12C-mutated colorectal cancer: Safety and efficacy for phase Ib full expansion cohort

被引：15

作者：

Kuboki, Y. ^{[1
]}

Yaeger, R. ^{[2
]}

Fakih, M. G. ^{[3
]}

Strickler, J. H. ^{[4
]}

Masuishi, T. ^{[5
]}

Kim, E. J. ^{[6
]}

Bestvina, C. M. ^{[7
]}

Langer, C. J. ^{[8
]}

Krauss, J. C. ^{[9
]}

Puri, S. ^{[10
]}

Cardona, P. ^{[11
]}

Chan, E. ^{[12
]}

Tran, Q. ^{[12
]}

Hong, D. S. ^{[13
]}

机构：

[1] Natl Canc Ctr Hosp East, Expt Therapeut & GI Oncol Dept, Kashiwa, Japan

[2] Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY USA

[3] City Hope Comprehens Canc Ctr, Med Oncol & Therapeut Res, Duarte, CA USA

[4] Duke Univ, Dept Med, Med Ctr, Durham, NC USA

[5] Aichi Canc Ctr Hosp, Clin Oncol Dept, Nagoya, Aichi, Japan

[6] UC Davis Comprehens Canc Ctr, Hematol Oncol Internal Med, Sacramento, CA USA

[7] Univ Chicago, Dept Med, Sect Hematol Oncol, Chicago, IL USA

[8] Univ Penn, Hematol Oncol, Philadelphia, PA USA

[9] Univ Michigan, Hematol Oncol Internal Med, Ann Arbor, MI USA

[10] Huntsman Canc Inst, Med Hematol & Oncol, Salt Lake City, UT USA

[11] Amgen Inc, Clin Pharmacol Modeling & Simulat, Thousand Oaks, CA USA

[12] Amgen Inc, Res & Dev, Thousand Oaks, CA USA

[13] Univ Texas MD Anderson Canc Ctr, Invest Canc Therapeut, Houston, TX USA

来源：

ANNALS OF ONCOLOGY | 2022年 / 33卷 / 07期

关键词：

D O I：

10.1016/j.annonc.2022.07.453

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

315O

引用

页码：S680 / S681

页数：2

共 50 条

[41] Sotorasib versus docetaxel for previously treated KRAS G12C-mutated non-small-cell lung cancer: a plain language summary
de Langen, Adrianus Johannes
Johnson, Melissa L.
Mazieres, Julien
Dingemans, Anne-Marie C.
Mountzios, Giannis
Pless, Miklos
Wolf, Juergen
Schuler, Martin
Lena, Herve
Skoulidis, Ferdinandos
Yoneshima, Yasuto
Kim, Sang-We
Linardou, Helena
Novello, Silvia
van der Wekken, Anthonie J.
Chen, Yuanbin
Peters, Solange
Felip, Enriqueta
Solomon, Benjamin J.
Ramalingam, Suresh S.
Dooms, Christophe
Lindsay, Colin R.
Ferreira, Carlos Gil
Blais, Normand
Obiozor, Cynthia C.
Wang, Yang
Mehta, Bhakti
Varrieur, Tracy
Ngarmchamnanrith, Gataree
Stollenwerk, Bjoern
Waterhouse, David
Paz-Ares, Luis
FUTURE ONCOLOGY, 2025,
[42] Real World Efficacy and Safety of Sotorasib in US Veterans with KRAS G12C Mutated Non-Small Cell Lung Cancer
Zhou, K. I.
Lin, C.
Tseng, C. -L.
Ramnath, N.
Dowell, J. E.
Kelley, M. J.
JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S337 - S338
[43] Sotorasib in KRAS G12C-mutated NSCLC: A multicenter real-world experience from the expanded access program in Germany
Althoff, F. C.
Stratmann, J. A.
Doebel, P.
Hunerlituerkoglu, A. N.
Frost, N.
Christopoulos, P.
Zum Bueschenfelde, C. Meyer
Alt, J.
Webendoerfer, M.
Kaldune, S.
Tritchkova, G.
Waller, C. F.
Braess, J.
Kopp, H-G.
Grohe, C.
Schumann, C.
Griesinger, F.
Kuon, J. B.
Sebastian, M.
Reinmuth, N.
ANNALS OF ONCOLOGY, 2023, 34
[44] Patient-reported outcomes from the CodeBreaK 200 phase III trial comparing sotorasib versus docetaxel in KRAS G12C-mutated NSCLC
Waterhouse, D. M.
Rothschild, S.
Dooms, C.
Mennecier, B.
Bozorgmehr, F.
Majem, M.
van den Heuvel, M.
Linardou, H.
Chul-Cho, B.
Roberts-Thomson, R.
Okamoto, I.
Blais, N.
Schvartsman, G.
Holmskov, K.
Chmielewska, I.
Forster, M.
Stollenwerk, B.
Obiozor, C. C.
Wang, Y.
Novello, S.
JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (04) : S37 - S38
[45] Sotorasib (960 mg or 240 mg) once daily in patients with previously treated KRAS G12C-mutated advanced NSCLC
Hochmair, Maximilian J.
Vermaelen, Karim
Mountzios, Giannis
Carcereny, Enric
Dooms, Christophe
Lee, Se-Hoon
Morocz, Eva
Kato, Terufumi
Ciuleanu, Tudor-Eliade
Dy, Grace K.
Parente, Barbara
O'Byrne, Kenneth J.
Chu, Quincy S.
De Castro Junior, Gilberto
Girard, Nicolas
Snyder, Wendy
Tran, Qui
Kormany, William
Houk, Brett
Mehta, Bhakti
Curioni-Fontecedro, Alessandra
EUROPEAN JOURNAL OF CANCER, 2024, 208
[46] Long-term benefit of sotorasib in patients with KRAS G12C-mutated non-small-cell lung cancer: plain language summary
Dy, Grace K.
Govindan, Ramaswamy
Velcheti, Vamsidhar
Falchook, Gerald S.
Italiano, Antoine
Wolf, Juergen
Sacher, Adrian G.
Takahashi, Toshiaki
Ramalingam, Suresh S.
Dooms, Christophe
Kim, Dong-Wan
Addeo, Alfredo
Desai, Jayesh
Schuler, Martin
Tomasini, Pascale
Hong, David S.
Lito, Piro
Tran, Qui
Jones, Simon
Anderson, Abraham
Hindoyan, Antreas
Snyder, Wendy
Skoulidis, Ferdinandos
Li, Bob T.
FUTURE ONCOLOGY, 2024, 20 (03) : 113 - 120
[47] A phase 1b study evaluating the safety and efficacy of sotorasib, a KRASG12C inhibitor, in combination with trametinib, a MEK inhibitor, in KRAS p.G12C-Mutated Solid Tumors
Ramalingam, Suresh
Fakih, Marwan
Strickler, John
Govindan, Ramaswamy
Li, Bob T.
Goldberg, Sarah
Gandara, David
Burns, Timothy
Barve, Minal
Shu, Catherine
Frank, Richard
Sohal, Davendra
Jafarinasabian, Pegah
Dai, Tian
Mather, Omar
Hong, David
MOLECULAR CANCER THERAPEUTICS, 2021, 20 (12)
[48] Twelve-month progression-free survival with sotorasib and panitumumab in KRAS G12C mutant metastatic colorectal cancer
Kavgaci, Gozde
Dizdar, Omer
Yalcin, Suayib
ANTI-CANCER DRUGS, 2024, 35 (05) : 459 - 461
[49] Safety and efficacy of HS-10370 in KRAS G12C-mutated solid tumors including non-small cell lung cancer (NSCLC)
Dong, Xiaorong
Meng, Xiangjiao
Zhang, Yan
Wang, Yan
Chen, Jianhua
Han, Liang
Wang, Qiming
Lin, Zhong
Wei, Hongying
Lin, Siheng
Li, Chuan
Wu, Qiong
CANCER RESEARCH, 2024, 84 (07)
[50] Nonclinical Safety Profile of Sotorasib, a KRASG12C-Specific Covalent Inhibitor for the Treatment of KRAS p.G12C-Mutated Cancer
Ishida, Katsu
Werner, Jonathan A.
Davies, Rhian
Fan, Fan
Thomas, Barbara
Wahlstrom, Jan
Lipford, James Russell
Monticello, Thomas
INTERNATIONAL JOURNAL OF TOXICOLOGY, 2021, 40 (05) : 427 - 441

← 1 2 3 4 5 →